Disorders with M. O. G.
antibodies are a problematic disease in the nervous system, with clinical performance being complex and often involving multi-system congestion. Early identification and normalisation of the disease are essential for improving prognosis. Diagnosis of the disease requires a combination of clinical performance, imaging, laboratory testing and pathological activation.
Platforms can assist in matching teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. Treatment and management of M. O.
G. antibodies require individualized development of treatment programs, typically including drug therapy, rehabilitation interventions, regular follow-up, and other multidimensional management. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many formerly difficult-to-treat neurological diseases have been significantly improved.
Treatment needs to closely monitor efficacy and adverse reactions, adapting timely to changes in the course of the disease. Multidisciplinary collaboration (MDT) is particularly important for the integrated management of diseases related to MOG antibodies. The platform serves China International Medical Service System, a team of domestic and foreign authorities in the field of neural systems, providing the following services to patients: 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.